Connect with us


Inbentus needs half a million euros to advance the development of respirators

The company Inbentus specialized in medical technology and founded during the Covid-19 crisis, launches a campaign through Crowdcube. One of the objectives of this round is to raise $486,000 (€400,000) that will be destined to the development of the high-tech ICU ventilator. Inbentus estimates that by 2027 an investment of $10.3 billion (€8.5 billion) in invasive respirators will be required worldwide.



Inbentus is in search of capital to further develop and opened this week a financing round of $608,000 (€500,000) through the Crowdcube platform, as Rafael Valverde, CEO of Inbentus, explained. 

The company, which already has a product developed that consists of a respirator to respond to the crisis of Covid-19, has so far raised $170,000 (€140,000) of private funding. In addition, Inbentus has been supported by the Administration with the granting of two non-refundable aids for an amount exceeding $243,000 (€200,000), said Valverde. 

The objective of this round is divided into two: on the one hand, the company expects to raise $486,000 (€400,000) that will be destined for the development of the high-tech ICU ventilator, while, on the other hand, the remaining $121,600 (€100,000 will serve to boost the sales of the equipment. Likewise, Inbentus has the objective of commercialization in emerging markets.

“We have developed an economical and accessible solution that did not exist until today in the market for respirators,” said the company’s executive.  

If you want to find more details about the company Inbentus and its most recent financing round it opened on Crowdcube, download for free the Born2Invest mobile app. Our companion app will keep you up to date with the latest business news in the world. 

Inbentus expects to raise $486,000 (€400,000) that will be destined to the development of the high-tech ICU ventilator

The company has diagnosed two problems that it wants to transform into opportunities. 10% of COVID-19’s active cases need artificial ventilation and there is a low supply of highly reliable turbine ventilators, but a high demand in emerging countries. The target market for this sector covers more than 3 billion people worldwide. In 2021, Inbentus will continue with the development of its equipment, a respirator whose sales price can be around $12,000 (€10,000). 

In addition, Inbentus estimates that by 2027 an investment of $10.3 billion (€8.5 billion) in invasive respirators will be required worldwide. Another of the company’s future objectives is, once the commercialization phase has been developed in emerging countries and Europe, to make the leap to BME Growth, formerly the Alternative Stock Market (MAB) in a target scenario from 2023 to 2025. The truth is that for the moment there is nothing concrete.  

In the founding team of the company is the founder of Clerhp Estructuras 

The founding team of Inbentus, in addition to Valverde, is composed of Juan Andrés Romero, founder of Clerhp Estructuras, a listed Spanish engineering and construction company, and José Ramón García, CEO of La Comarca Food Group. In addition, the company has in its team of advisor Mariano Martinez, head of the ICU of the Reina Sofia Hospital in Murcia.

In the market where Inbentus is located, there are other competitors in Europe and the United States such as Medtronic, Hamilton Medical, Honeywell, Dräger or General Electric Healthcare. In Brazil, Magnamed stands out and in China, Aeomed.


(Featured image by blickpixel via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.